Search
Patexia Research
Case number 1:23-cv-00374

AbbVie, Inc. v. Teva Pharmaceuticals, Inc. > Documents

Date Field Doc. No.Description (Pages)
Jul 3, 2023 9 ANSWER to 1 Complaint, Affirmative Defenses, COUNTERCLAIM against AbbVie Inc. by Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 07/03/2023) (15)
Jul 3, 2023 10 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 07/03/2023) (1)
May 19, 2023 8 SO ORDERED Granting 7 Stipulation and Proposed Order (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 7/3/2023). Signed by Judge Richard G. Andrews on 5/19/2023. (nms) (Entered: 05/19/2023) (5)
May 18, 2023 7 STIPULATION and [Proposed] Order Regarding Teva Defendants by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/18/2023) (5)
May 4, 2023 6 MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin - filed by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/04/2023) (9)
May 4, 2023 N/A SO ORDERED, re (D.I. 6 in 23-cv-470-RGA; D.I. 6 in 23-cv-374-RGA; D.I. 6 in 23-cv-448-RGA) MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin, filed by AbbVie Inc.. Signed by Judge Richard G. Andrews on 5/4/2023. Associated Cases: 1:23-cv-00374-RGA, 1:23-cv-00448-RGA, 1:23-cv-00470-RGA(nms) (Entered: 05/04/2023) (0)
Apr 5, 2023 N/A Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:23-cv-00362-RGA, 1:23-cv-00374-RGA (rjb) (Entered: 04/05/2023) (0)
Apr 3, 2023 1 COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Main Document) (16)
Apr 3, 2023 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 04/03/2023) (3)
Apr 3, 2023 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/21/2023. Date of Expiration of Patent: 07/29/2039.Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 04/03/2023) (1)
Apr 3, 2023 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (vfm) (Entered: 04/03/2023) (1)
Apr 3, 2023 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (vfm) (Entered: 04/03/2023) (1)
Apr 3, 2023 N/A No Summons Issued. (vfm) (Entered: 04/03/2023) (0)
Apr 3, 2023 1 COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Exhibit A) (30)
Apr 3, 2023 1 COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Civil Cover Sheet) (2)
Menu